ARTICLE | Company News
Chiron, Crucell, DSM Biologics N.V. deal
June 21, 2004 7:00 AM UTC
CHIR licensed rights to use CRXL's PER.C6 technology for research and preclinical development of its portfolio of recombinant monoclonal antibody products. CRXL and its contract manufacturing partner,...